FSH

Mira Launches Ovum Wand to Predict Menopause and Monitor Fertility Status for Women Over 35

Retrieved on: 
Tuesday, August 2, 2022
Algorithm, Time, Education, GLOBE, Awareness, Urine, Woman, Menopause, SAN, LH, CEO, Research, Puberty, Ovulation, Luteinizing hormone, FSH, Hormone replacement therapy, Machine learning, FDA, PDG, Fertility, Reproductive health, Pregnanediol, Hormone, Birth control

They can also be used to monitor fertility and find possible causes of reproductive issues for women after 35.

Key Points: 
  • They can also be used to monitor fertility and find possible causes of reproductive issues for women after 35.
  • The Mira Ovum Wand can provide information to help understand perimenopause, predict menopause and address the symptoms early.
  • To predict approaching menopause or track changes in fertility, a person needs to test over several days for two or more cycles.
  • Mira offers a whole line of hormone test wands, including Mira Fertility (luteinizing hormone), Mira Fertility Plus (estrone-3-glucuronide and luteinizing hormone) and Mira Confirm (pregnanediol glucuronide).

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

Retrieved on: 
Thursday, July 28, 2022
Pulmonary embolism, Liver, Edema, Neoplasm, BPH, Hypercalcaemia, Capsule, Testosterone, Birth, LHRH, Woman, Gynecomastia, Radiation, Sleep apnea, Gonadotropin, Trauma, Cardiovascular disease, Androgen, DVT, Luteinizing hormone, Prostate cancer, Orchiectomy, FSH, Cryptorchidism, Primary, Risk, Adult, Deep vein thrombosis, Hypogonadism, T4, Chronic lung disease, Safety, Cancer, Orchitis, VTE, Thyroid, Hypergonadotropic hypogonadism, Suicidal ideation, Heart, Klinefelter syndrome, CIII, Patient, PE, Thyroxine-binding globulin, Serum, Breast cancer, Man, Blood pressure, Depression, Spermatogenesis, Obesity, Methyltestosterone, BP, MACE, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Virtual Primary Care Helps Patients Build Better, Faster Connections With Doctors

Retrieved on: 
Tuesday, July 12, 2022
Conditional sentence, Anxiety, Gaps, Patient, Insurance, FSH, Mortality, GLOBE, Physician, Depression, Time, PCP, Health insurance, Telehealth

Virtual Primary Care connects patients to primary care doctors that are part of the FSH virtual practice, who can provide care for preventive and chronic issues, as well as urgent care concerns.

Key Points: 
  • Virtual Primary Care connects patients to primary care doctors that are part of the FSH virtual practice, who can provide care for preventive and chronic issues, as well as urgent care concerns.
  • Virtual Primary Care patients are also spending 30 minutes (on average) with a FSH primary care doctor.
  • With Virtual Primary Care, FSH doctors can now deliver whole-person, digital-first care for the mind and body.
  • We help them save time and money with safe, convenient, high-quality virtual care solutions - Telemedicine, Virtual Mental Health and Virtual Primary Care.

Natalist Introduces New Products to Support Every Stage of the Reproductive Journey

Retrieved on: 
Thursday, June 23, 2022
Time, CVS Pharmacy, Fertility, Choline, Eye, Luteinizing hormone, Constipation, Q10 (temperature coefficient), Natalism, Testosterone, Reproductive health, Vitamin, Brain, Pregnancy, Pharmacy, Neural tube defect, Estradiol, Disease, TSH, General manager, DHA, Nutrient, FSH, Partnership, Follicle-stimulating hormone, Fertility testing, Food, LH, Hormone, Multimedia, Instagram, OBGYN, Food and Drug Administration, Nausea, Target, Iron, Woman, Rite Aid, Birth control, Dietary supplement

AUSTIN, Texas, June 23, 2022 /PRNewswire/ -- Natalist, a women's health company founded and led by moms that offers consumers fertility, pregnancy, and postpartum essentials that are 100% plastic neutral, announced today the launch of four new products, including CoQ10 Gummies, Prenatal Gummies, Pregnancy Test Strips, and an at-home collection Women's Fertility Test. These products are now available at Natalist.com and retailers nationwide as the brand rapidly expands to bring high-quality, doctor-recommended products and resources to people at every stage of their reproductive journeys.

Key Points: 
  • These products are now available at Natalist.com and retailers nationwide as the brand rapidly expands to bring high-quality, doctor-recommended products and resources to people at every stage of their reproductive journeys.
  • "Natalist is here to change that with fertility, pregnancy, and postpartum products designed by moms and doctors to support every step of your reproductive journey."
  • Natalist is uniquely positioned to serve women and families on their path to parenthood with its comprehensive and affordable products.
  • Natalist takes the guesswork out of reproductive health with thoughtfully designed products that empower consumers to support every step of their fertility health and reproductive journeys.

First Stop Health Named One of Inc. Magazine's Best Workplaces of 2022

Retrieved on: 
Wednesday, May 11, 2022
Achievement, COVID-19, Patient, Feedback, Leadership, FSH, 100 Best Workplaces in Europe, Inc. (magazine), Inc., GLOBE, Intelligence, Management, Tourism, Telehealth

"We are so proud to be ranked by Inc. as one of America's best workplaces," said FSH President Teira Gunlock.

Key Points: 
  • "We are so proud to be ranked by Inc. as one of America's best workplaces," said FSH President Teira Gunlock.
  • We used this time to reinvent how we collaborated with and cared for one another.
  • The Inc. Best Workplaces list is the result of a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture, whether operating in a physical or virtual facility.
  • We help them save time and money with safe, convenient, high-quality virtual care solutions Telemedicine, Virtual Mental Health and Virtual Primary Care.

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

Retrieved on: 
Monday, May 9, 2022
T4, LHRH, Birth, Androgen, Methyltestosterone, CIII, Hypergonadotropic hypogonadism, Orchitis, Hypogonadism, Blood pressure, Woman, Thyroid, Neoplasm, Spermatogenesis, Liver, MACE, Breast cancer, Deep vein thrombosis, DVT, Cardiovascular disease, Radiation, Chronic lung disease, Suicidal ideation, Patient, Trauma, Pulmonary embolism, Gynecomastia, Testosterone, Sleep apnea, Edema, Heart, Luteinizing hormone, Risk, Gonadotropin, Cancer, VTE, Obesity, Primary, Klinefelter syndrome, Orchiectomy, FSH, Adult, Thyroxine-binding globulin, PE, Cryptorchidism, Prostate cancer, Hypercalcaemia, Serum, BP, BPH, Depression, Capsule, Man, Safety, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at the 2022 American Urological Association Annual Meeting taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans May 13-16, 2022.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

First Stop Health Helps Patients Throughout COVID-19 Pandemic With Speedy, Convenient, Safe Access to Virtual Care

Retrieved on: 
Thursday, March 10, 2022
Time, Work, COVID, Patient, Depression, ROI, GLOBE, FSH, Solution, Anxiety, COVID-19, CEO, Love, Pharmaceutical industry, Hospital, Telehealth

During that time, First Stop Health (FSH) has helped to keep patients safe with convenient, fast and affordable virtual access to care for physical and mental well-being support.

Key Points: 
  • During that time, First Stop Health (FSH) has helped to keep patients safe with convenient, fast and affordable virtual access to care for physical and mental well-being support.
  • Now, more than half of FSH members have access to Virtual Mental Health, which virtually connects patients with mental health counselors for 24/7 access to care for anxiety, stress, depression, substance use, work and family concerns, and more.
  • "The pandemic has rapidly accelerated virtual care adoption and helped businesses see virtual care as an investment and a key component of a complete employee benefits strategy."
  • We help them save time and money with safe, convenient, high-quality virtual care solutions - Telemedicine, Virtual Mental Health and Virtual Primary Care.

Global IVF Services Market (2022 to 2031) - Featuring Betamedics, CHA Fertility Center and Morpheus IVF Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Health, Biotechnology, Benchmark, Public health, AFC, Semen, Patient, Human services, Follicle-stimulating hormone, PRP, Hospital, Journal, Reproductive technology, Create, Woman, Egg, Organization, Fertility clinic, Hair follicle, Growth, Infertility, Fertility, INR, Glass, AMH, Platelet-rich plasma, Coronavirus, Fertilisation, Indian Journal of Community Medicine, FSH, Hormone, IVF, Marketing, Mineral oil, Birth control, Genetics

The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.

Key Points: 
  • The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.
  • The main types of cycles in IVF services markets are fresh IVF cycles (non-donor), thawed IVF cycles (non-donor) and donor egg IVF cycles.
  • The high cost of IVF services limits the in-vitro fertilization (IVF) services market.
  • The high cost of IVF services makes it unavailable to low- and middle-income populations negatively affecting the IVF services' market growth.

EMD Serono Launches New Sustainable Slim Pack for Fertility Medication

Retrieved on: 
Thursday, February 17, 2022
Carbon, Abdominal pain, Calendar, Stroke, Thrombus, Itchy, Bruise, Cyst, Hospital, Face, Epistasis, Ovarian hyperstimulation syndrome, ART, Anovulation, OHSS, Pregnancy, Merck Serono, Birth, Female, Structured Product Labeling, Neoplasm, Woman, RFF, Research, Pen, FSH, Vitamin, Skin, Life, PCOS, Heart, Diarrhea, CO2, Rash, Headache, Risk, Infection, Use, Brain, Health, Death, Weight gain, Breast, Hypothalamus, Miscarriage, Pain, Vomiting, Carbon footprint, Blood, Thrombosis, Multiple sclerosis, Asthma, Patient, Cancer, Bronchoscopic lung volume reduction (BLVR), Transport, Polycystic ovary syndrome, Efficiency, Infertility, Merck Group, Uterus, FDA, KPMG, Nausea, Multimedia, Stomach, Allergy, Pharmaceutical industry, Recycling, Birth control, Medical imaging, Beekeeping, Merck

ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.

Key Points: 
  • ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.
  • "Our new Slim Pack isan initiative we hope will drive convenience while reducing our overall carbon footprint."
  • Slim Pack will lower GONAL-f RFF* Redi-ject's global carbon footprint by 33%.
  • Plastic savings calculated using the unit weight of individual plastic tray and multiplied by the total production volume in one calendar year, once Slim Pack fully implemented across all fertility pens worldwide.

Endometriosis Market Spotlight Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Revenue Opportunity, Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Pharmaceutical, Health, Women, Consumer, Patient, Probability, United States Congress, FSH, Gonadotropin-releasing hormone, Bayer, Endometriosis, Woman, Adult, AbbVie, Infertility, Pain scale, Ageing, Clinical trial, Triptorelin, LHR, Birth control, Pharmaceutical industry, Takeda

The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III.

Key Points: 
  • The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III.
  • The US has a substantial lead in the number of endometriosis clinical trials globally.
  • Bayer has the highest number of completed clinical trials for endometriosis, with 45 trials.
  • Bayer leads industry sponsors with the highest overall number of clinical trials for endometriosis, followed by AbbVie and Takeda.